<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838030</url>
  </required_header>
  <id_info>
    <org_study_id>ECAALA</org_study_id>
    <nct_id>NCT02838030</nct_id>
  </id_info>
  <brief_title>Efficacy of Aspirin and L-arginine in High Risk Preeclamptic</brief_title>
  <official_title>Efficacy of the Combination of Acetylsalicylic Acid and L-arginine to Prevent Preeclampsia in Pregnant High Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PhD Ernesto Javier Ramírez Lizardo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PhD Sylvia Elena Totsuka Sutto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PhD Fernando Grover Páez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MD Diego Hernández Molina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, the incidence of preeclampsia ranges from 2 to 10% of pregnancies. The World
      Health Organization (WHO) estimates that the incidence of preeclampsia is seven times higher
      in developing countries than in developed (2.8% and 0.4%). In Mexico it is estimated that
      preeclampsia - eclampsia is a major cause of maternal and perinatal morbidity and mortality.
      Because it is an idiopathic heterogeneous syndrome associated with endothelial damage, so far
      there is no effective treatment to decrease the morbidity and mortality of this entity, so it
      is necessary to strengthen prevention; the use of aspirin alone is inconclusive, in addition
      to the information the investigators have reduced the effect of these strategies on arterial
      stiffness; Moreover, it has been observed that L-arginine lowers blood pressure in this
      population. It is for this that is of interest to know the efficacy and safety of the
      combination of L-arginine low dose, which is known as an important eNOS in NO production
      substrate, and aspirin for its qualities of antiinflammatory and anticoagulant in the
      prevention of preeclampsia and also determine their effect on arterial stiffness as a
      noninvasive method, as is the applanation tonometry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will conduct a clinical trial, double-blind, randomized and placebo control group female
      patients with 12 weeks of gestation have one or more risk factors for developing
      preeclampsia. 2 groups will be formed with 82 patients each, chance will determine the
      intervention (acetylsalicylic + L-arginine acetylsalicylic acid or acid + placebo). At the
      beginning and end of the intervention clinical and laboratory determinations, the end will be
      determined in both groups the incidence of preeclampsia, severity and number needed to treat
      is made. The data obtained were analyzed using SPSS statistical software version 22. It was
      considered statistically significant at p &lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>from 20 weeks gestation until 37 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severity of preeclampsia</measure>
    <time_frame>from 20 weeks gestation until 37 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary edema maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulopathy maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal damage maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal mortality</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal mortality</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>High Risk Pregnancy</condition>
  <arm_group>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <other_name>arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for L-arginine)</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <other_name>Magnesia calcined</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant before 12 weeks of gestation

          -  High risk of preeclampsia

          -  Signature of informed consent in writing

        Exclusion Criteria:

          -  Noncompliance &gt; 20% of drug intake

          -  Lack of tolerability L-arginine or acetylsalicylic acid

          -  Compliance with at least one non-inclusion criteria during the course of the study

          -  Serious adverse event

          -  Withdrawal of consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonel García Benavides, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonel García Benavides, PhD</last_name>
    <phone>10585200</phone>
    <email>drleonelgb@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antiguo Hospital Civil Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Hernandez Mora, Obstetrician</last_name>
      <phone>3331700456</phone>
      <email>frank.gine@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Leonel Garcia Benavides</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>L-arginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

